Clinical Trial Update: Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II study evaluating MCS110 with PDR001 in advanced malignancies; completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Carcinoma
• Melanoma
• Pancreatic Carcinoma
• Triple-negative Breast Cancer

Drugs mentioned

• MCS110
• PDR001

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Triple Negative Breast Cancer, Pancreatic Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-08-11